- Home
- BDL vs MAIA Comparison
BDL vs MAIA Comparison
Compare BDL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDL
- MAIA
- Stock Information
- Founded
- BDL 1959
- MAIA 2018
- Country
- BDL United States
- MAIA United States
- Employees
- BDL N/A
- MAIA N/A
- Industry
- BDL Restaurants
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- BDL Consumer Discretionary
- MAIA Health Care
- Exchange
- BDL Nasdaq
- MAIA Nasdaq
- Market Cap
- BDL 57.7M
- MAIA 56.3M
- IPO Year
- BDL N/A
- MAIA 2022
- Fundamental
- Price
- BDL $31.76
- MAIA $1.57
- Analyst Decision
- BDL
- MAIA
- Analyst Count
- BDL 0
- MAIA 0
- Target Price
- BDL N/A
- MAIA N/A
- AVG Volume (30 Days)
- BDL 715.0
- MAIA 385.0K
- Earning Date
- BDL 08-12-2025
- MAIA 08-11-2025
- Dividend Yield
- BDL 1.73%
- MAIA N/A
- EPS Growth
- BDL 41.91
- MAIA N/A
- EPS
- BDL 2.32
- MAIA N/A
- Revenue
- BDL $201,851,000.00
- MAIA N/A
- Revenue This Year
- BDL N/A
- MAIA N/A
- Revenue Next Year
- BDL N/A
- MAIA N/A
- P/E Ratio
- BDL $13.33
- MAIA N/A
- Revenue Growth
- BDL 8.84
- MAIA N/A
- 52 Week Low
- BDL $22.61
- MAIA $1.40
- 52 Week High
- BDL $35.98
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- BDL 51.40
- MAIA 46.97
- Support Level
- BDL $30.00
- MAIA $1.50
- Resistance Level
- BDL $31.34
- MAIA $1.64
- Average True Range (ATR)
- BDL 0.46
- MAIA 0.08
- MACD
- BDL 0.04
- MAIA 0.01
- Stochastic Oscillator
- BDL 51.61
- MAIA 40.74
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.